{"hq_id":"hq-c-org-000492","name":"Prednisone","context":"human_adult","risk_level":"moderate","schema":"legacy","note":"Synthesis unavailable: compound lacks vectorizable regulatory classifications. Raw safety data returned.","data":{"risk_level":"moderate","summary":"Prednisone (CAS 53-03-2) carries a low_to_moderate risk profile driven primarily by long-term systemic use adverse effects rather than acute toxicity. Short courses (5–14 days) for acute inflammatory conditions (asthma exacerbation, allergic reactions, severe contact dermatitis) are generally safe with minimal long-term sequelae, though HPA suppression can occur even with short courses. Chronic use (weeks to months to years) for autoimmune diseases causes a predictable, dose-dependent adverse effect burden: osteoporosis requiring preventive bisphosphonate therapy, steroid-induced diabetes especially in predisposed individuals, HPA axis suppression requiring slow tapering on discontinuation, immunosuppression increasing risk of opportunistic infections (including Pneumocystis pneumonia with high-dose regimens), and cardiovascular risk (hypertension, dyslipidemia, accelerated atherosclerosis). The minimum effective dose and shortest necessary duration are guiding principles. No carcinogenicity concern from prednisone itself."},"meta":{"synthesis_version":"n/a","timestamp":"2026-10-28T20:01:48.573Z"},"_notice":"ALETHEIA output is reference data, not professional advice. Not a substitute for primary agency sources or qualified professionals. See https://aletheia.holisticquality.io/disclaimer.","_disclaimer_url":"https://aletheia.holisticquality.io/disclaimer","available_contexts":["human_adult","human_child","aquatic_life","human_teen","human_elderly","human_infant","human_pregnant"]}